| 8001 | CGA levels | GCST90468732 | 3.97e-03 |
| 8002 | HDL cholesterol | GCST000755 | 3.97e-03 |
| 8003 | CKAP4/LAMP3 ratio | GCST90314073 | 3.97e-03 |
| 8004 | Malignant melanoma of skin, excluding all cancers (controls excluding all cancers) | FING00000749 | 3.97e-03 |
| 8005 | Abnormalities of forces of labour | FING00000003 | 3.97e-03 |
| 8006 | PLXNB2 levels | GCST90470266 | 3.96e-03 |
| 8007 | GZMA/TNFRSF8 ratio | GCST90315014 | 3.95e-03 |
| 8008 | aseg rh intensity Cerebellum-Cortex | GCST90003781 | 3.95e-03 |
| 8009 | LDL cholesterol | GCST000759 | 3.95e-03 |
| 8010 | Saturated fatty acids to total fatty acids percentage | GCST90499958 | 3.95e-03 |
| 8011 | SOD3 levels | GCST90470706 | 3.95e-03 |
| 8012 | CD46/SIAE ratio | GCST90313835 | 3.95e-03 |
| 8013 | Creatinine levels | GCST90278624 | 3.94e-03 |
| 8014 | Haemorrhoidal disease | GCST90014033 | 3.94e-03 |
| 8015 | ISEI occupational score | GCST90446160 | 3.94e-03 |
| 8016 | T1 FreeSurfer DK lh precentral thickness | GCST90385645 | 3.93e-03 |
| 8017 | SLITRK6 levels | GCST90470671 | 3.93e-03 |
| 8018 | IDP dMRI TBSS MO Superior corona radiata R | GCST90003976 | 3.92e-03 |
| 8019 | Prolapse of vaginal walls | genitourinary | UKBB00000712 | 3.92e-03 |
| 8020 | Forced expiratory volume in 1-second (FEV1) | Spirometry | UKBB00000251 | 3.92e-03 |
| 8021 | ICD10 O12: Gestational oedema and proteinuria without hypertension | GCST90454231 | 3.92e-03 |
| 8022 | Cystatin C levels in bottom 99% of individuals by creatinine levels | GCST90566734 | 3.92e-03 |
| 8023 | CD79B/TNFRSF13B ratio | GCST90313902 | 3.92e-03 |
| 8024 | Eosinophil count | GCST004606 | 3.92e-03 |
| 8025 | Pregnenolone sulfate levels | GCST90199873 | 3.91e-03 |
| 8026 | CDH17 levels | GCST90468669 | 3.91e-03 |
| 8027 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T136 | ECGU000136 | 3.91e-03 |
| 8028 | Blood urea nitrogen (BUN, maximum, inv-norm transformed) | GCST90475162 | 3.91e-03 |
| 8029 | RNF43 levels | GCST90470486 | 3.90e-03 |
| 8030 | Primary open-angle glaucoma, strict | FING00001214 | 3.90e-03 |
| 8031 | Triglycerides in very large HDL (UKB data field 23557) | GCST90269654 | 3.90e-03 |
| 8032 | pro-brain natriuretic peptide (proBNP, mean, inv-norm transformed) | GCST90476312 | 3.90e-03 |
| 8033 | aparc-a2009s lh volume S-calcarine | GCST90002968 | 3.89e-03 |
| 8034 | ANKRD54 levels | GCST90468311 | 3.88e-03 |
| 8035 | Total lipids in small VLDL | GCST90499849 | 3.88e-03 |
| 8036 | Systolic blood pressure, manual reading, adjusted by medication | Cardiovascular measurement | UKBB00000811 | 3.86e-03 |
| 8037 | aparc-DKTatlas rh area insula | GCST90003296 | 3.86e-03 |
| 8038 | IDP dMRI TBSS MO Posterior corona radiata R | GCST90003978 | 3.86e-03 |
| 8039 | OLFM4 levels | GCST90470121 | 3.85e-03 |
| 8040 | PLA2G15/SMPDL3A ratio | GCST90315663 | 3.85e-03 |
| 8041 | Takes medication for high cholesterol? | GCST90475208 | 3.85e-03 |
| 8042 | Sebaceous cyst (PheCode 706.2) | GCST90476213 | 3.85e-03 |
| 8043 | X-24544 levels | GCST90200636 | 3.84e-03 |
| 8044 | SPTLC1 levels | GCST90427130 | 3.84e-03 |
| 8045 | Concentration of VLDL particles | GCST90500250 | 3.84e-03 |
| 8046 | Diseases of the digestive system | FING00000429 | 3.83e-03 |
| 8047 | UGDH levels | GCST90471006 | 3.83e-03 |
| 8048 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T258 | ECGA000258 | 3.83e-03 |
| 8049 | AGRP levels | GCST90468256 | 3.82e-03 |
| 8050 | DNMBP levels | GCST90469023 | 3.82e-03 |
| 8051 | Operation code - hip replacement/revision | Operations | UKBB00000558 | 3.82e-03 |
| 8052 | Urine X-24796 levels in chronic kidney disease | GCST90266800 | 3.81e-03 |
| 8053 | S100A13 levels | GCST90470514 | 3.81e-03 |
| 8054 | Citrate levels | GCST90497206 | 3.81e-03 |
| 8055 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T6 | ECGA000006 | 3.81e-03 |
| 8056 | OGN levels | GCST90470119 | 3.81e-03 |
| 8057 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T103 | ECGU000103 | 3.80e-03 |
| 8058 | Allergic contact dermatitis | FING00000068 | 3.80e-03 |
| 8059 | TOR1AIP1 levels | GCST90470935 | 3.80e-03 |
| 8060 | TDP1 levels | GCST90470826 | 3.80e-03 |
| 8061 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T275 | ECGA000275 | 3.80e-03 |
| 8062 | LRP11/ROR1 ratio | GCST90315330 | 3.79e-03 |
| 8063 | Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia | GCST90624744 | 3.79e-03 |
| 8064 | Ximenoylcarnitine (C26:1) levels | GCST90200149 | 3.79e-03 |
| 8065 | Pulse pressure, combined automated + manual reading | Cardiovascular measurement | UKBB00000719 | 3.79e-03 |
| 8066 | CC2D1A/CRADD ratio | GCST90313663 | 3.78e-03 |
| 8067 | Lysophosphatidylcholine (26:0) [sn2] levels | GCST90025428 | 3.78e-03 |
| 8068 | EIF4G1 levels | GCST90469097 | 3.78e-03 |
| 8069 | Appendicular lean mass | GCST90000027 | 3.78e-03 |
| 8070 | Urine glucosaminate levels in chronic kidney disease | GCST90265179 | 3.78e-03 |
| 8071 | DARS1/USP8 ratio | GCST90314407 | 3.77e-03 |
| 8072 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 125) | GCST90320944 | 3.77e-03 |
| 8073 | Celiac disease (PheCode 557.1) | GCST90044158 | 3.77e-03 |
| 8074 | Left ventricular end systole anterospetal wall thickness | GCST90278513 | 3.76e-03 |
| 8075 | DTI TBSS MO Middle cerebellar peduncle | GCST90384620 | 3.76e-03 |
| 8076 | CD46/TIMP1 ratio | GCST90313837 | 3.76e-03 |
| 8077 | CR2 levels | GCST90468852 | 3.75e-03 |
| 8078 | Histidine levels (UKB data field 23463) | GCST90269560 | 3.75e-03 |
| 8079 | Principal component-derived dietary pattern 58 | GCST90133061 | 3.75e-03 |
| 8080 | Other noninflammatory disorders of uterus, except cervix | FING00001079 | 3.74e-03 |
| 8081 | Phospholipids to total lipids in very large VLDL percentage (UKB data field 23584) | GCST90269681 | 3.74e-03 |
| 8082 | Right-hemisphere visual network to right-hemisphere control network white-matter structural connectivity | GCST90302779 | 3.74e-03 |
| 8083 | Basophil count variance | GCST90565682 | 3.74e-03 |
| 8084 | Pulse pressure, automated reading, adjusted by medication | Cardiovascular measurement | UKBB00000716 | 3.74e-03 |
| 8085 | IDP dMRI TBSS L3 Cingulum hippocampus R | GCST90004207 | 3.72e-03 |
| 8086 | Free cholesterol in small HDL (UKB data field 23577) | GCST90269674 | 3.71e-03 |
| 8087 | Ascending aorta strain | GCST90267388 | 3.70e-03 |
| 8088 | RBP5 levels | GCST90470439 | 3.69e-03 |
| 8089 | Middle diffusion tensor imaging along the perivascular space index | GCST90455544 | 3.69e-03 |
| 8090 | TNC/VCAM1 ratio | GCST90315927 | 3.69e-03 |
| 8091 | Duodenal ulcer | GCST90270928 | 3.69e-03 |
| 8092 | CPM levels | GCST90240598 | 3.68e-03 |
| 8093 | 5-hydroxyindole sulfate levels | GCST90200050 | 3.68e-03 |
| 8094 | GSR levels | GCST90469410 | 3.67e-03 |
| 8095 | Urine X-24798 levels in chronic kidney disease | GCST90266802 | 3.67e-03 |
| 8096 | Creatinine levels | GCST90132719 | 3.67e-03 |
| 8097 | Corneal resistance factor | GCST90100568 | 3.67e-03 |
| 8098 | GPRC5C levels | GCST90469398 | 3.66e-03 |
| 8099 | Hypothyroidism, drug reimbursement | FING00000655 | 3.66e-03 |
| 8100 | Enterocolitis due to Clostridium difficile | FING00000507 | 3.66e-03 |
| 8101 | HEXIM1 levels | GCST90469447 | 3.65e-03 |
| 8102 | Triglycerides in medium LDL (UKB data field 23543) | GCST90269640 | 3.64e-03 |
| 8103 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T140 | ECGU000140 | 3.64e-03 |
| 8104 | CTSZ/SMPDL3A ratio | GCST90314322 | 3.63e-03 |
| 8105 | GNPDA2 levels | GCST90469374 | 3.63e-03 |
| 8106 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T255 | ECGU000255 | 3.62e-03 |
| 8107 | Octadecenedioylcarnitine (C18:1-DC) levels | GCST90199970 | 3.62e-03 |
| 8108 | IL2RB levels | GCST90469586 | 3.62e-03 |
| 8109 | aparc-a2009s rh volume S-collat-transv-ant | GCST90003048 | 3.62e-03 |
| 8110 | Operation code - spinal laminectomy | Operations | UKBB00000564 | 3.61e-03 |
| 8111 | MESD/WWP2 ratio | GCST90315426 | 3.60e-03 |
| 8112 | EDAR/SDC4 ratio | GCST90314585 | 3.60e-03 |
| 8113 | CXCL3/MGLL ratio | GCST90314345 | 3.60e-03 |
| 8114 | Appendicular lean mass | GCST90000025 | 3.59e-03 |
| 8115 | ENPP2 levels | GCST90469115 | 3.59e-03 |
| 8116 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T89 | ECGU000089 | 3.59e-03 |
| 8117 | Male-pattern baldness | GCST006661 | 3.59e-03 |
| 8118 | ITGB5/S100A4 ratio | GCST90315233 | 3.59e-03 |
| 8119 | Ratio of omega-6 fatty acids to total fatty acids | GCST90092935 | 3.59e-03 |
| 8120 | HAVCR1 levels | GCST90469431 | 3.59e-03 |
| 8121 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 64) | GCST90320883 | 3.58e-03 |
| 8122 | Low density lipoprotein cholesterol levels | GCST90278638 | 3.58e-03 |
| 8123 | Phospholipids to Total Lipids in Small VLDL percentage | GCST90499895 | 3.58e-03 |
| 8124 | BTN2A1/SMOC2 ratio | GCST90313549 | 3.57e-03 |
| 8125 | IMPACT levels | GCST90469611 | 3.57e-03 |
| 8126 | FAM3B levels | GCST90469186 | 3.57e-03 |
| 8127 | IPCEF1/SMAD1 ratio | GCST90315185 | 3.57e-03 |
| 8128 | TNFSF11 levels | GCST90012044 | 3.56e-03 |
| 8129 | DAG1/F2R ratio | GCST90314374 | 3.56e-03 |
| 8130 | Offspring birth weight | GCST005314 | 3.56e-03 |
| 8131 | IDP dMRI TBSS L2 External capsule L | GCST90004156 | 3.55e-03 |
| 8132 | TBC1D5 levels | GCST90470811 | 3.55e-03 |
| 8133 | ACY3 levels | GCST90468213 | 3.54e-03 |
| 8134 | GPR15L levels | GCST90469396 | 3.54e-03 |
| 8135 | Autoimmune diseases | FING00000131 | 3.54e-03 |
| 8136 | Percentage of trisyalated structures in total plasma glycans (GP97) | GCST90668541 | 3.54e-03 |
| 8137 | FABP5 levels | GCST90469177 | 3.54e-03 |
| 8138 | FCRL1/TCL1A ratio | GCST90314795 | 3.53e-03 |
| 8139 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T32 | ECGA000032 | 3.53e-03 |
| 8140 | Citrate levels | GCST90497200 | 3.52e-03 |
| 8141 | CDKN2D/MANF ratio | GCST90313989 | 3.52e-03 |
| 8142 | aseg lh intensity Pallidum | GCST90003771 | 3.51e-03 |
| 8143 | Basal cell carcinoma, including avohilmo, excluding all cancers (controls excluding all cancers) | FING00000143 | 3.51e-03 |
| 8144 | MMP1/MMP3 ratio | GCST90315461 | 3.50e-03 |
| 8145 | SERPINI1 levels | GCST90470602 | 3.50e-03 |
| 8146 | CD34 levels | GCST90468626 | 3.50e-03 |
| 8147 | APOA1 levels | GCST90269537 | 3.50e-03 |
| 8148 | STIP1 levels | GCST90470764 | 3.49e-03 |
| 8149 | IL15/IL18BP ratio | GCST90315148 | 3.49e-03 |
| 8150 | rfMRI amplitudes (ICA100 node 11) | GCST90004599 | 3.49e-03 |
| 8151 | Rheumatoid arthritis (rheumatoid factor and/or anti-cyclic citrullinated peptide seropositive) | GCST90132227 | 3.49e-03 |
| 8152 | JAM2/TGFBR2 ratio | GCST90315238 | 3.48e-03 |
| 8153 | Pustulosis palmaris et plantaris | FING00001233 | 3.48e-03 |
| 8154 | Type 1 diabetes, definitions combined | FING00001380 | 3.47e-03 |
| 8155 | Triglycerides in IDL (UKB data field 23529) | GCST90269626 | 3.47e-03 |
| 8156 | Triacylglycerol_47:4_[M+NH4]1+ levels | GCST90060391 | 3.46e-03 |
| 8157 | Acute pulmonary heart disease (PheCode 415.1) | GCST90475944 | 3.46e-03 |
| 8158 | Liver iron content | GCST90016674 | 3.46e-03 |
| 8159 | CDHR5 levels | GCST90468680 | 3.46e-03 |
| 8160 | Lymphoid neoplasms (B-cell phenocluster) | GCST90624736 | 3.45e-03 |
| 8161 | ALCAM/CDH5 ratio | GCST90313234 | 3.45e-03 |
| 8162 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T128 | ECGA000128 | 3.45e-03 |
| 8163 | IFIH1 levels | GCST90423689 | 3.44e-03 |
| 8164 | Polyunsaturated fatty acid levels | GCST90502140 | 3.43e-03 |
| 8165 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497868 | 3.43e-03 |
| 8166 | Mean reticulocyte volume | GCST90025975 | 3.43e-03 |
| 8167 | APPL2 levels | GCST90468343 | 3.43e-03 |
| 8168 | SERPINE2 levels | GCST90470597 | 3.43e-03 |
| 8169 | Behenoyl dihydrosphingomyelin (d18:0/22:0) levels | GCST90200059 | 3.43e-03 |
| 8170 | TCTN3 levels | GCST90470823 | 3.42e-03 |
| 8171 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T93 | ECGU000093 | 3.42e-03 |
| 8172 | FUT8/TNFSF14 ratio | GCST90314895 | 3.42e-03 |
| 8173 | Volume of right accessory basal nucleus | GCST90474907 | 3.42e-03 |
| 8174 | Benign neoplasm: Choroid | FING00000170 | 3.42e-03 |
| 8175 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T34 | ECGA000034 | 3.42e-03 |
| 8176 | CXCL8 levels | GCST90468934 | 3.41e-03 |
| 8177 | TIMP3 levels | GCST90470871 | 3.40e-03 |
| 8178 | Operation code - coronary artery bypass grafts (cabg) | Operations | UKBB00000556 | 3.40e-03 |
| 8179 | CLTA levels | GCST90468791 | 3.40e-03 |
| 8180 | CD1C/CD207 ratio | GCST90313745 | 3.39e-03 |
| 8181 | CPXM1/LGMN ratio | GCST90314220 | 3.39e-03 |
| 8182 | GSTA1/SULT2A1 ratio | GCST90314996 | 3.38e-03 |
| 8183 | FOLH1 levels | GCST90425661 | 3.38e-03 |
| 8184 | NOMO1 levels | GCST90470060 | 3.38e-03 |
| 8185 | Phospholipids in large LDL | GCST90498053 | 3.37e-03 |
| 8186 | CALCOCO1 levels | GCST90468530 | 3.36e-03 |
| 8187 | F2R/SNX9 ratio | GCST90314736 | 3.36e-03 |
| 8188 | Glaucoma (primary open-angle) | GCST90011768 | 3.36e-03 |
| 8189 | BANK1 levels | GCST90468421 | 3.36e-03 |
| 8190 | Basophil count | GCST90002293 | 3.36e-03 |
| 8191 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T52 | ECGA000052 | 3.35e-03 |
| 8192 | Plasma ascorbic acid 2-sulfate levels in chronic kidney disease | GCST90264832 | 3.35e-03 |
| 8193 | Polyunsaturated fatty acid levels | GCST90502142 | 3.34e-03 |
| 8194 | Plasma N,N,N-trimethyl-5-aminovalerate levels in chronic kidney disease | GCST90265671 | 3.34e-03 |
| 8195 | Childhood asthma (age<16) (more control exclusions) | FING00000270 | 3.33e-03 |
| 8196 | MMP9/PLAUR ratio | GCST90315470 | 3.33e-03 |
| 8197 | ART3/GPC1 ratio | GCST90313361 | 3.33e-03 |
| 8198 | Mean corpuscular volume | GCST90002392 | 3.33e-03 |
| 8199 | Hearing difficulty and hearing difficulty with background noise | GCST90245768 | 3.33e-03 |
| 8200 | ENO2/TACC3 ratio | GCST90314670 | 3.33e-03 |
| 8201 | Treatment/medication code - metformin | Medications | UKBB00000851 | 3.33e-03 |
| 8202 | Phospholipids in medium HDL (UKB data field 23567) | GCST90269664 | 3.32e-03 |
| 8203 | SMAD1/ZBTB16 ratio | GCST90315853 | 3.31e-03 |
| 8204 | Succinoyltaurine levels | GCST90200235 | 3.31e-03 |
| 8205 | Dysmenorrheic pain severity | GCST006656 | 3.31e-03 |
| 8206 | MPHOSPH8 levels | GCST90469934 | 3.31e-03 |
| 8207 | CALCOCO1/TJAP1 ratio | GCST90313611 | 3.30e-03 |
| 8208 | IDP SWI T2star right pallidum | GCST90003870 | 3.30e-03 |
| 8209 | Hematocrit | GCST004604 | 3.29e-03 |
| 8210 | IDP dMRI ProbtrackX L1 cgc r | GCST90004251 | 3.29e-03 |
| 8211 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79) | GCST90320642 | 3.28e-03 |
| 8212 | Diastolic blood pressure, manual reading | Blood pressure | UKBB00000180 | 3.28e-03 |
| 8213 | ILKAP levels | GCST90469608 | 3.28e-03 |
| 8214 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T43 | ECGA000043 | 3.27e-03 |
| 8215 | CST3/IGFBP6 ratio | GCST90314293 | 3.27e-03 |
| 8216 | ESAM/FUT8 ratio | GCST90314711 | 3.27e-03 |
| 8217 | Creatinine levels | GCST90497236 | 3.26e-03 |
| 8218 | Concentration of small VLDL particles | GCST90499868 | 3.26e-03 |
| 8219 | Phosphatidylcholine_34:4_[M+H]1+/Phosphatidylethanolamine_37:4_[M+H]1+/Phosphatidate_39:5_[M+NH4]1+ levels | GCST90060295 | 3.25e-03 |
| 8220 | HNRNPK levels | GCST90469469 | 3.25e-03 |
| 8221 | IDP T1 FAST ROIs R intracalc cortex | GCST90002498 | 3.25e-03 |
| 8222 | FKBP7 levels | GCST90469245 | 3.24e-03 |
| 8223 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T85 | ECGA000085 | 3.24e-03 |
| 8224 | PBLD levels | GCST90470163 | 3.23e-03 |
| 8225 | CEACAM21 levels | GCST90468694 | 3.22e-03 |
| 8226 | SPINT2 levels | GCST90470728 | 3.21e-03 |
| 8227 | APRT/PSME1 ratio | GCST90313338 | 3.21e-03 |
| 8228 | Fasting plasma glucose | GCST90566420 | 3.21e-03 |
| 8229 | BCAN/NPTXR ratio | GCST90313482 | 3.20e-03 |
| 8230 | TXLNA levels | GCST90470989 | 3.20e-03 |
| 8231 | Gamma-CEHC levels | GCST90199864 | 3.20e-03 |
| 8232 | Free Cholesterol in VLDL | GCST90500217 | 3.20e-03 |
| 8233 | EPPK1 levels | GCST90469137 | 3.20e-03 |
| 8234 | GRAP2/SNX9 ratio | GCST90314988 | 3.20e-03 |
| 8235 | PTPN1/WWP2 ratio | GCST90315746 | 3.19e-03 |
| 8236 | AHCY/HSPA1A ratio | GCST90313211 | 3.19e-03 |
| 8237 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498519 | 3.19e-03 |
| 8238 | OTUD6B levels | GCST90470136 | 3.19e-03 |
| 8239 | AmygNuclei rh volume Central-nucleus | GCST90002662 | 3.19e-03 |
| 8240 | Low-density lipoprotein levels (MTAG) | GCST90179148 | 3.17e-03 |
| 8241 | CCL13/CCL17 ratio | GCST90313674 | 3.17e-03 |
| 8242 | Triacylglycerol_54:4_[M+NH4]1+ levels | GCST90060540 | 3.17e-03 |
| 8243 | DAPK2 levels | GCST90240877 | 3.17e-03 |
| 8244 | SEMA4D/TXNDC5 ratio | GCST90315824 | 3.16e-03 |
| 8245 | Operation code - spine or back surgery | Operations | UKBB00000565 | 3.16e-03 |
| 8246 | CD83/IL12A_IL12B ratio | GCST90313905 | 3.16e-03 |
| 8247 | Phosphoglycerides levels | GCST90499265 | 3.15e-03 |
| 8248 | CORO1A levels | GCST90468832 | 3.15e-03 |
| 8249 | OMD/SPP1 ratio | GCST90315586 | 3.15e-03 |
| 8250 | Eosinophill percentage (UKB data field 30210) | GCST90468069 | 3.15e-03 |
| 8251 | Female genital prolapse | Noninflammatory disorders of female genital tract | UKBB00000244 | 3.14e-03 |
| 8252 | CETN2/PRTFDC1 ratio | GCST90314030 | 3.14e-03 |
| 8253 | PARP1 levels | GCST90470160 | 3.14e-03 |
| 8254 | EIF4B levels | GCST90469094 | 3.13e-03 |
| 8255 | Operative procedures - Angiocardiography of left side of heart NEC | Summary Operations | UKBB00000572 | 3.13e-03 |
| 8256 | MTSS2 levels | GCST90469961 | 3.13e-03 |
| 8257 | PODXL2/SCG3 ratio | GCST90315700 | 3.13e-03 |
| 8258 | ANXA3/ENO2 ratio | GCST90313281 | 3.12e-03 |
| 8259 | CSF1 levels | GCST90468881 | 3.12e-03 |
| 8260 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T227 | ECGU000227 | 3.11e-03 |
| 8261 | AXIN1 levels | GCST90468405 | 3.10e-03 |
| 8262 | CD46/SELP ratio | GCST90313834 | 3.10e-03 |
| 8263 | HMOX2 levels | GCST90469466 | 3.10e-03 |
| 8264 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 85) | GCST90320904 | 3.10e-03 |
| 8265 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T485 | ECGU000485 | 3.10e-03 |
| 8266 | IDP dMRI TBSS ISOVF Superior corona radiata R | GCST90004501 | 3.10e-03 |
| 8267 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T81 | ECGA000081 | 3.10e-03 |
| 8268 | HNMT/SETMAR ratio | GCST90315069 | 3.09e-03 |
| 8269 | Total phospholipid levels in lipoprotein particles | GCST90500110 | 3.09e-03 |
| 8270 | Lung function (FVC) | GCST007429 | 3.09e-03 |
| 8271 | Hip fracture | GCST90161240 | 3.09e-03 |
| 8272 | hemoglobin (maximum, inv-norm transformed) | GCST90475372 | 3.09e-03 |
| 8273 | DNAJB14 levels | GCST90427235 | 3.08e-03 |
| 8274 | Type 2 diabetes | GCST90468151 | 3.08e-03 |
| 8275 | DIABLO/DOK2 ratio | GCST90314464 | 3.08e-03 |
| 8276 | CD160 levels | GCST90468599 | 3.08e-03 |
| 8277 | Oral glucose tolerance test-0h | GCST90566421 | 3.07e-03 |
| 8278 | LGALS8/TXNDC5 ratio | GCST90315321 | 3.06e-03 |
| 8279 | 3-hydroxybutyrate levels (UKB data field 23474) | GCST90269571 | 3.06e-03 |
| 8280 | High-grade serous epithelial ovarian cancer | GCST90244168 | 3.06e-03 |
| 8281 | Birth year infant mortality rates | GCST90095047 | 3.06e-03 |
| 8282 | LBR/LGALS8 ratio | GCST90315294 | 3.06e-03 |
| 8283 | MATN2 levels | GCST90469864 | 3.06e-03 |
| 8284 | FCGR2B/NOS3 ratio | GCST90314794 | 3.06e-03 |
| 8285 | SCARA5/TGFBI ratio | GCST90315809 | 3.06e-03 |
| 8286 | CD69/PPP1R2 ratio | GCST90313882 | 3.05e-03 |
| 8287 | Total testosterone levels | GCST90012114 | 3.05e-03 |
| 8288 | RRM2 levels | GCST90470501 | 3.05e-03 |
| 8289 | CA4/TGFBR2 ratio | GCST90313588 | 3.03e-03 |
| 8290 | Chronic obstructive pulmonary disease x current smoker interaction (main effect) | GCST90016591 | 3.03e-03 |
| 8291 | ESAM/JAM2 ratio | GCST90314712 | 3.03e-03 |
| 8292 | Melanocytic naevi of trunk | FING00000800 | 3.03e-03 |
| 8293 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T261 | ECGA000261 | 3.02e-03 |
| 8294 | diastolic blood pressure (DBP, mean, inv-normal transformed) | GCST90475255 | 3.02e-03 |
| 8295 | Graves' disease | GCST90018627 | 3.02e-03 |
| 8296 | TNFAIP8 levels | GCST90470898 | 3.02e-03 |
| 8297 | Neurofibromatosis, type 2 | FING00000867 | 3.01e-03 |
| 8298 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T467 | ECGU000467 | 3.01e-03 |
| 8299 | CD58 levels | GCST90468638 | 3.01e-03 |
| 8300 | CEACAM16 levels | GCST90468689 | 3.01e-03 |
| 8301 | Diffuse idiopathic skeletal hyperostosis flow score | GCST90134532 | 3.00e-03 |
| 8302 | Type 1 diabetes | GCST90013791 | 2.99e-03 |
| 8303 | DPP6/NRCAM ratio | GCST90314542 | 2.98e-03 |
| 8304 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T47 | ECGA000047 | 2.98e-03 |
| 8305 | Hemoglobin concentration | GCST90002310 | 2.97e-03 |
| 8306 | Haematocrit percentage | Blood count | UKBB00000292 | 2.97e-03 |
| 8307 | CD83/TNFRSF4 ratio | GCST90313907 | 2.97e-03 |
| 8308 | AGRP levels | GCST90240217 | 2.96e-03 |
| 8309 | PON2/PON3 ratio | GCST90315703 | 2.96e-03 |
| 8310 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502389 | 2.96e-03 |
| 8311 | Non-mucinous epithelial ovarian cancer | GCST90244167 | 2.96e-03 |
| 8312 | Thyroid stimulating hormone levels within normal range in pregnancy | GCST90435195 | 2.95e-03 |
| 8313 | PKLR/UBAC1 ratio | GCST90315660 | 2.95e-03 |
| 8314 | DNAJA2/HCLS1 ratio | GCST90314502 | 2.95e-03 |
| 8315 | Blood urea nitrogen (BUN, mean, inv-norm transformed) | GCST90475165 | 2.95e-03 |
| 8316 | Breast cancer | GCST007236 | 2.94e-03 |
| 8317 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 79) | GCST90320898 | 2.94e-03 |
| 8318 | Small cell lung carcinoma | GCST004746 | 2.94e-03 |
| 8319 | Cerebrospinal fluid 3-hydroxy-2-ethylpropionate levels | GCST90317964 | 2.94e-03 |
| 8320 | CDSN/WFDC12 ratio | GCST90313999 | 2.94e-03 |
| 8321 | Hip minimal joint space width | GCST90281365 | 2.93e-03 |
| 8322 | NUDC levels | GCST90470102 | 2.93e-03 |
| 8323 | EGFL7 levels | GCST90469083 | 2.93e-03 |
| 8324 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T122 | ECGA000122 | 2.93e-03 |
| 8325 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T37 | ECGA000037 | 2.93e-03 |
| 8326 | Phosphoglycerides levels | GCST90499259 | 2.92e-03 |
| 8327 | wg rh intensity-contrast parahippocampal | GCST90003842 | 2.91e-03 |
| 8328 | Systemic connective tissue disorders | FING00001350 | 2.91e-03 |
| 8329 | C20:4 Lysophosphatidylcholine levels in chronic kidney disease | GCST90257570 | 2.91e-03 |
| 8330 | RBFOX3 levels | GCST90470432 | 2.91e-03 |
| 8331 | Chronic pain (confirmatory factor analysis Factor 18) | GCST90309352 | 2.91e-03 |
| 8332 | aparc-Desikan lh volume cuneus | GCST90002772 | 2.91e-03 |
| 8333 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T33 | ECGA000033 | 2.90e-03 |
| 8334 | Right-hemisphere visual network to right-hemisphere visual network white-matter structural connectivity | GCST90302774 | 2.90e-03 |
| 8335 | Polyunsaturated fatty acid levels | GCST90499266 | 2.90e-03 |
| 8336 | MEPE/SOST ratio | GCST90315420 | 2.89e-03 |
| 8337 | Fracture of forearm | GCST90281273 | 2.88e-03 |
| 8338 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 57) | GCST90320876 | 2.88e-03 |
| 8339 | mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed) | GCST90475450 | 2.88e-03 |
| 8340 | IDP dMRI TBSS ICVF Cingulum hippocampus L | GCST90004364 | 2.88e-03 |
| 8341 | ATG4A/NSFL1C ratio | GCST90313368 | 2.88e-03 |
| 8342 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T218 | ECGU000218 | 2.88e-03 |
| 8343 | UBXN1 levels | GCST90471004 | 2.88e-03 |
| 8344 | Inguinal hernia | digestive | UKBB00000362 | 2.87e-03 |
| 8345 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475350 | 2.87e-03 |
| 8346 | Mild obesity-related type 2 diabetes | GCST90026415 | 2.87e-03 |
| 8347 | CPA1/PLA2G1B ratio | GCST90314205 | 2.87e-03 |
| 8348 | MPI/TACC3 ratio | GCST90315491 | 2.87e-03 |
| 8349 | Haemoglobin concentration | Blood count | UKBB00000293 | 2.87e-03 |
| 8350 | Facial pigmentation measurement (UV light) | GCST90002283 | 2.86e-03 |
| 8351 | RCC1 levels | GCST90470443 | 2.86e-03 |
| 8352 | Nerve, nerve root and plexus disorders | FING00000862 | 2.86e-03 |
| 8353 | FUT8/SORT1 ratio | GCST90314892 | 2.85e-03 |
| 8354 | Other disorders of veins | FING00001040 | 2.85e-03 |
| 8355 | TG levels | GCST90470851 | 2.85e-03 |
| 8356 | CYB5R2 levels | GCST90468937 | 2.85e-03 |
| 8357 | Polyarthrosis | FING00001181 | 2.84e-03 |
| 8358 | aseg rh volume Cerebellum-Cortex | GCST90002636 | 2.84e-03 |
| 8359 | Phospholipids to total lipids ratio in small HDL | GCST90092953 | 2.84e-03 |
| 8360 | wg rh intensity-contrast superiortemporal | GCST90003856 | 2.83e-03 |
| 8361 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T9 | ECGA000009 | 2.83e-03 |
| 8362 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T97 | ECGU000097 | 2.83e-03 |
| 8363 | Triglycerides in HDL (UKB data field 23410) | GCST90269507 | 2.83e-03 |
| 8364 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T121 | ECGA000121 | 2.83e-03 |
| 8365 | Biological Sibling: Asthma | GCST90476372 | 2.82e-03 |
| 8366 | Inguinal hernia | Hernia | UKBB00000363 | 2.81e-03 |
| 8367 | CASP3/SERPINB9 ratio | GCST90313642 | 2.81e-03 |
| 8368 | PTPRF levels | GCST90470381 | 2.81e-03 |
| 8369 | IL15 levels | GCST90469556 | 2.80e-03 |
| 8370 | Glutamine levels (UKB data field 23461) | GCST90269558 | 2.80e-03 |
| 8371 | FOXO3 levels | GCST90469266 | 2.80e-03 |
| 8372 | Irregular menstrual cycle/bleeding | genitourinary | UKBB00000379 | 2.80e-03 |
| 8373 | Ulcerative colitis | GCST004133 | 2.80e-03 |
| 8374 | LDL cholesterol | GCST002222 | 2.79e-03 |
| 8375 | IDP dMRI ProbtrackX ICVF cgh l | GCST90004381 | 2.79e-03 |
| 8376 | Blood urea nitrogen (BUN, minimum, inv-norm transformed) | GCST90475168 | 2.79e-03 |
| 8377 | SPART levels | GCST90470719 | 2.78e-03 |
| 8378 | Renal failure (PheCode 585) | GCST90476118 | 2.78e-03 |
| 8379 | ZNRD2 levels | GCST90471103 | 2.78e-03 |
| 8380 | AMBP/HYOU1 ratio | GCST90313255 | 2.77e-03 |
| 8381 | Acne | FING00000010 | 2.76e-03 |
| 8382 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T145 | ECGU000145 | 2.76e-03 |
| 8383 | Phospholipid levels in medium HDL | GCST90092900 | 2.76e-03 |
| 8384 | Glaucoma, exfoliation | FING00000580 | 2.76e-03 |
| 8385 | Sicca syndrome [Sjögren] | FING00001304 | 2.76e-03 |
| 8386 | Platelet count at delivery | GCST90302227 | 2.76e-03 |
| 8387 | aseg global volume 4th-Ventricle | GCST90002600 | 2.76e-03 |
| 8388 | CALCOCO1/INPPL1 ratio | GCST90313603 | 2.76e-03 |
| 8389 | aseg global volume-ratio BrainSegVol-to-eTIV | GCST90002612 | 2.75e-03 |
| 8390 | Dermatophytosis of nail (PheCode 110.11) | GCST90475562 | 2.75e-03 |
| 8391 | GLOD4 levels | GCST90469359 | 2.74e-03 |
| 8392 | Glaucoma (primary open-angle) | GCST90011766 | 2.74e-03 |
| 8393 | Total fatty acid levels | GCST90502723 | 2.74e-03 |
| 8394 | Rheumatoid arthritis | FING00001267 | 2.74e-03 |
| 8395 | Cerebrospinal fluid unidentified metabolite levels (HILIC Metabolomics ID: 8.07_212.10) | GCST90291805 | 2.73e-03 |
| 8396 | Pulse pressure, combined automated + manual reading, adjusted by medication | Cardiovascular measurement | UKBB00000721 | 2.73e-03 |
| 8397 | Pulse pressure, automated reading | Cardiovascular measurement | UKBB00000715 | 2.73e-03 |
| 8398 | PRSS8 levels | GCST90470345 | 2.73e-03 |
| 8399 | PAFAH1B3 levels | GCST90470145 | 2.73e-03 |
| 8400 | Chronic obstructive pulmonary disease in non-current smokers | GCST90016594 | 2.73e-03 |
| 8401 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T1 | ECGA000001 | 2.73e-03 |
| 8402 | CA13/TYMP ratio | GCST90313568 | 2.73e-03 |
| 8403 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T124 | ECGA000124 | 2.72e-03 |
| 8404 | IDP SWI T2star right putamen | GCST90003868 | 2.72e-03 |
| 8405 | DCTN6 levels | GCST90468960 | 2.72e-03 |
| 8406 | Pulse pressure | GCST90472785 | 2.71e-03 |
| 8407 | Non-cancer illness code, self-reported - hypothyroidism/myxoedema | Medical conditions | UKBB00000518 | 2.71e-03 |
| 8408 | X-13435 levels | GCST90243811 | 2.71e-03 |
| 8409 | aparc-a2009s lh area G-cuneus | GCST90003307 | 2.71e-03 |
| 8410 | AXIN1/NFATC1 ratio | GCST90313415 | 2.71e-03 |
| 8411 | Qualifications - NVQ or HND or HNC or equivalent | Education | UKBB00000730 | 2.71e-03 |
| 8412 | Lysophosphatidylethanolamine-P_20:0_[M-H]1- levels | GCST90060147 | 2.71e-03 |
| 8413 | CLPS/PLA2G1B ratio | GCST90314140 | 2.70e-03 |
| 8414 | IDP dMRI TBSS MD Cerebral peduncle L | GCST90004042 | 2.70e-03 |
| 8415 | HEXIM1/NUB1 ratio | GCST90315049 | 2.70e-03 |
| 8416 | PIKFYVE levels | GCST90470235 | 2.70e-03 |
| 8417 | Calcium levels (UKB data field 30680) | GCST90468065 | 2.69e-03 |
| 8418 | IQGAP2/STX4 ratio | GCST90315190 | 2.69e-03 |
| 8419 | TPK1 levels | GCST90470943 | 2.69e-03 |
| 8420 | Carcinoma in situ of breast, intraductal (controls excluding all cancers) | FING00000240 | 2.69e-03 |
| 8421 | Calcium levels | GCST90025990 | 2.69e-03 |
| 8422 | PTPRM/SELE ratio | GCST90315753 | 2.69e-03 |
| 8423 | MMP1/SERPINB6 ratio | GCST90315462 | 2.69e-03 |
| 8424 | Myocardial infarction | circulatory system | UKBB00000491 | 2.69e-03 |
| 8425 | MOCS2 levels | GCST90469928 | 2.69e-03 |
| 8426 | Basal cell carcinoma, excluding all cancers (controls excluding all cancers) | FING00000142 | 2.68e-03 |
| 8427 | DOK2/SNX9 ratio | GCST90314539 | 2.68e-03 |
| 8428 | CPB1/REG1B ratio | GCST90314213 | 2.68e-03 |
| 8429 | BIN2/TMSB10 ratio | GCST90313515 | 2.68e-03 |
| 8430 | MITD1/WWP2 ratio | GCST90315458 | 2.67e-03 |
| 8431 | Saturated fatty acids levels | GCST90502659 | 2.67e-03 |
| 8432 | Plasma cystathionine levels in chronic kidney disease | GCST90264974 | 2.67e-03 |
| 8433 | BSG levels | GCST90468472 | 2.66e-03 |
| 8434 | CDC27 levels | GCST90468664 | 2.66e-03 |
| 8435 | SNCG levels | GCST90470695 | 2.66e-03 |
| 8436 | DPP7 levels | GCST90469035 | 2.66e-03 |
| 8437 | 5alpha-androstan-3beta,17beta-diol disulfate levels | GCST90199835 | 2.66e-03 |
| 8438 | Triacylglycerol_50:3_[M+NH4]1+ levels | GCST90060468 | 2.66e-03 |
| 8439 | Volume of right cortico-amygdaloid transition area | GCST90475018 | 2.65e-03 |
| 8440 | PCBP2 levels | GCST90470167 | 2.65e-03 |
| 8441 | MAP2 levels | GCST90469853 | 2.65e-03 |
| 8442 | ADM/CLMP ratio | GCST90313197 | 2.64e-03 |
| 8443 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T184 | ECGU000184 | 2.64e-03 |
| 8444 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T66 | ECGA000066 | 2.64e-03 |
| 8445 | eosinophil (fraction, maximum, inv-norm transformed) | GCST90475297 | 2.64e-03 |
| 8446 | Valine levels | GCST90500177 | 2.63e-03 |
| 8447 | TBCC/WWP2 ratio | GCST90315911 | 2.63e-03 |
| 8448 | F7/VASN ratio | GCST90314745 | 2.63e-03 |
| 8449 | RRM2B/SMAD1 ratio | GCST90315788 | 2.63e-03 |
| 8450 | IDP dMRI TBSS ICVF Cerebral peduncle R | GCST90004341 | 2.63e-03 |
| 8451 | TNFSF14 levels | GCST90274842 | 2.63e-03 |
| 8452 | Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor - Asthma | Medical conditions | UKBB00000098 | 2.62e-03 |
| 8453 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500975 | 2.62e-03 |
| 8454 | Cirrhosis | GCST90319877 | 2.62e-03 |
| 8455 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T102 | ECGU000102 | 2.61e-03 |
| 8456 | PLXNB3/SNAP23 ratio | GCST90315693 | 2.61e-03 |
| 8457 | Cholelithiasis | GCST90018599 | 2.61e-03 |
| 8458 | Descending aorta diameter | GCST90267391 | 2.60e-03 |
| 8459 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498092 | 2.60e-03 |
| 8460 | IL18R1 levels | GCST90469565 | 2.60e-03 |
| 8461 | Concentration of HDL particles | GCST90497414 | 2.60e-03 |
| 8462 | GLB1/IMPA1 ratio | GCST90314932 | 2.59e-03 |
| 8463 | CD22/FCRL1 ratio | GCST90313757 | 2.59e-03 |
| 8464 | Monounsaturated fatty acid levels | GCST90502359 | 2.59e-03 |
| 8465 | IL27 levels | GCST90012017 | 2.59e-03 |
| 8466 | IDP T1 FAST ROIs L supracalc cortex | GCST90002543 | 2.59e-03 |
| 8467 | CA9/CBLIF ratio | GCST90313595 | 2.59e-03 |
| 8468 | wg rh intensity-contrast frontalpole | GCST90003858 | 2.59e-03 |
| 8469 | TSTA3 levels | GCST90421854 | 2.58e-03 |
| 8470 | Second line medication for Crohn's disease | FING00001284 | 2.58e-03 |
| 8471 | IDP dMRI ProbtrackX MO str r | GCST90004024 | 2.58e-03 |
| 8472 | BA-exvivo rh volume MT | GCST90002860 | 2.58e-03 |
| 8473 | DTI TBSS MD Sagittal stratum L | GCST90384603 | 2.58e-03 |
| 8474 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T19 | ECGU000019 | 2.57e-03 |
| 8475 | TNFRSF17 levels | GCST90470908 | 2.57e-03 |
| 8476 | ALCAM/IL1RL2 ratio | GCST90313238 | 2.57e-03 |
| 8477 | LCN15 levels | GCST90469746 | 2.56e-03 |
| 8478 | CLIP2 levels | GCST90468782 | 2.56e-03 |
| 8479 | Triglycerides in very small VLDL (UKB data field 23522) | GCST90269619 | 2.56e-03 |
| 8480 | Total lipids in medium HDL | GCST90498597 | 2.56e-03 |
| 8481 | IDP dMRI TBSS MO Retrolenticular part of internal capsule R | GCST90003972 | 2.55e-03 |
| 8482 | ENTPD2 levels | GCST90469120 | 2.55e-03 |
| 8483 | ENO2/MGLL ratio | GCST90314663 | 2.55e-03 |
| 8484 | KRT19 levels | GCST90469717 | 2.55e-03 |
| 8485 | TAFA5 levels | GCST90470800 | 2.54e-03 |
| 8486 | FOLR2/HAVCR2 ratio | GCST90314865 | 2.53e-03 |
| 8487 | SELE levels | GCST90470566 | 2.52e-03 |
| 8488 | Stroke | GCST006906 | 2.51e-03 |
| 8489 | SNX2 levels | GCST90470701 | 2.50e-03 |
| 8490 | DBNL/EDAR ratio | GCST90314416 | 2.50e-03 |
| 8491 | Aspartate aminotransferase (AST, minimum, inv-norm transformed) | GCST90475124 | 2.50e-03 |
| 8492 | LGMN/TIMP1 ratio | GCST90315325 | 2.50e-03 |
| 8493 | DAPP1/PMVK ratio | GCST90314396 | 2.50e-03 |
| 8494 | CXCL11/DKK1 ratio | GCST90314334 | 2.50e-03 |
| 8495 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499111 | 2.48e-03 |
| 8496 | AZU1/MPO ratio | GCST90313425 | 2.48e-03 |
| 8497 | Ganglion and cyst of synovium, tendon, and bursa (PheCode 727.4) | GCST90476243 | 2.48e-03 |
| 8498 | KITLG levels | GCST90469691 | 2.47e-03 |
| 8499 | COL6A3/COLEC12 ratio | GCST90314173 | 2.47e-03 |
| 8500 | CX3CL1 levels | GCST90468921 | 2.46e-03 |
| 8501 | aparc-DKTatlas rh area parstriangularis | GCST90003283 | 2.46e-03 |
| 8502 | REG1A/TFF3 ratio | GCST90315764 | 2.45e-03 |
| 8503 | Trigger finger | FING00001376 | 2.45e-03 |
| 8504 | Benign neoplasm of other and unspecified endocrine glands | FING00000159 | 2.45e-03 |
| 8505 | P4HB/PPP1R12A ratio | GCST90315591 | 2.45e-03 |
| 8506 | PHLDB1 levels | GCST90470225 | 2.45e-03 |
| 8507 | KIR2DL2 levels | GCST90469684 | 2.44e-03 |
| 8508 | SCT levels | GCST90470557 | 2.44e-03 |
| 8509 | Monounsaturated fatty acid levels | GCST90502347 | 2.44e-03 |
| 8510 | Haemoglobin concentration (UKB data field 30020) | GCST90468074 | 2.42e-03 |
| 8511 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T257 | ECGU000257 | 2.42e-03 |
| 8512 | Psoriatic arthritis vs Cutaneous psoriasis | GCST90243957 | 2.42e-03 |
| 8513 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T186 | ECGU000186 | 2.41e-03 |
| 8514 | ANXA3/HCLS1 ratio | GCST90313282 | 2.41e-03 |
| 8515 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T84 | ECGU000084 | 2.41e-03 |
| 8516 | Dermatochalasis (PheCode 374.6) | GCST90475894 | 2.41e-03 |
| 8517 | Seborrhoeic keratosis | FING00001283 | 2.41e-03 |
| 8518 | GSTT2B levels | GCST90469415 | 2.41e-03 |
| 8519 | CPXM2 levels | GCST90468850 | 2.40e-03 |
| 8520 | CDC42BPB levels | GCST90468666 | 2.40e-03 |
| 8521 | ADAMTSL2 levels | GCST90468228 | 2.40e-03 |
| 8522 | ALPP/MSLN ratio | GCST90313250 | 2.39e-03 |
| 8523 | Atopic dermatitis | FING00000125 | 2.39e-03 |
| 8524 | ALB levels | GCST90025992 | 2.38e-03 |
| 8525 | Triglycerides in LDL | GCST90498472 | 2.38e-03 |
| 8526 | Cholesteryl esters to total lipids in small VLDL percentage (UKB data field 23601) | GCST90269698 | 2.37e-03 |
| 8527 | DLG4 levels | GCST90469001 | 2.37e-03 |
| 8528 | Neutrophil count | GCST90002352 | 2.36e-03 |
| 8529 | TP53BP1 levels | GCST90470936 | 2.36e-03 |
| 8530 | FAS levels | GCST90427702 | 2.36e-03 |
| 8531 | FLT3LG levels | GCST90469250 | 2.35e-03 |
| 8532 | N2-acetyl,N6,N6-dimethyllysine levels | GCST90200697 | 2.35e-03 |
| 8533 | RELT levels | GCST90470453 | 2.35e-03 |
| 8534 | GOLGA3 levels | GCST90469375 | 2.34e-03 |
| 8535 | Postmenopausal breast cancer | GCST90428116 | 2.33e-03 |
| 8536 | Biological Father: Coronary Artery / Coronary Heart Disease | GCST90475241 | 2.33e-03 |
| 8537 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T29 | ECGA000029 | 2.33e-03 |
| 8538 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T123 | ECGA000123 | 2.33e-03 |
| 8539 | SNX15 levels | GCST90470699 | 2.32e-03 |
| 8540 | FCRL6 levels | GCST90469209 | 2.32e-03 |
| 8541 | PDGFA/PRSS27 ratio | GCST90315616 | 2.31e-03 |
| 8542 | Volume of left basal nucleus | GCST90474877 | 2.31e-03 |
| 8543 | CD40/TNFRSF14 ratio | GCST90313830 | 2.30e-03 |
| 8544 | ALCAM/ICAM3 ratio | GCST90313237 | 2.30e-03 |
| 8545 | Triglyceride levels in very large HDL | GCST90132636 | 2.30e-03 |
| 8546 | CDH6 levels | GCST90468677 | 2.29e-03 |
| 8547 | Flat foot (PheCode 735.1) | GCST90476248 | 2.29e-03 |
| 8548 | Total diffusion tensor imaging along the perivascular space index | GCST90455546 | 2.29e-03 |
| 8549 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T216 | ECGA000216 | 2.29e-03 |
| 8550 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501045 | 2.29e-03 |
| 8551 | ING1 levels | GCST90469613 | 2.29e-03 |
| 8552 | X-21285 levels | GCST90200576 | 2.29e-03 |
| 8553 | aparc-a2009s lh volume G-cuneus | GCST90002935 | 2.29e-03 |
| 8554 | PTRHD1 levels | GCST90470389 | 2.29e-03 |
| 8555 | CD300C/FOLR2 ratio | GCST90313787 | 2.29e-03 |
| 8556 | Papulosquamous disorders | FING00001144 | 2.28e-03 |
| 8557 | Angina pectoris | FING00000086 | 2.28e-03 |
| 8558 | Phenylalanine levels (UKB data field 23468) | GCST90269565 | 2.28e-03 |
| 8559 | Acute myocardial infarction | Ischaemic heart diseases | UKBB00000011 | 2.27e-03 |
| 8560 | Ulcerative colitis | GCST90476067 | 2.27e-03 |
| 8561 | aparc-DKTatlas lh area pericalcarine | GCST90003253 | 2.27e-03 |
| 8562 | Creatinine levels | GCST90497237 | 2.26e-03 |
| 8563 | Volume of right whole amygdala | GCST90475057 | 2.26e-03 |
| 8564 | Cancer of bladder (PheCode 189.2) | GCST90475598 | 2.26e-03 |
| 8565 | ThalamNuclei lh volume L-Sg | GCST90002716 | 2.26e-03 |
| 8566 | Dermatitis and eczema | FING00000402 | 2.25e-03 |
| 8567 | DXO levels | GCST90469055 | 2.25e-03 |
| 8568 | X-11787 levels | GCST90200465 | 2.25e-03 |
| 8569 | Autorefraction - 3mm strong meridian angle (left) | Eyesight | UKBB00000067 | 2.24e-03 |
| 8570 | Melanomas of skin, dx or hx (PheCode 172.1) | GCST90475577 | 2.23e-03 |
| 8571 | BCR/PLXNA4 ratio | GCST90313497 | 2.23e-03 |
| 8572 | Primary angle-closure glaucoma (PheCode 365.2) | GCST90475876 | 2.23e-03 |
| 8573 | Hemoglobin concentration | GCST004615 | 2.23e-03 |
| 8574 | Estimated glomerular filtration rate, serum creatinine + cystain C | Other measurement | UKBB00000211 | 2.23e-03 |
| 8575 | Mean corpuscular haemoglobin concentration | Blood count | UKBB00000448 | 2.23e-03 |
| 8576 | CD5 levels | GCST90274773 | 2.23e-03 |
| 8577 | LAT2/YES1 ratio | GCST90315282 | 2.23e-03 |
| 8578 | PPP2R5A levels | GCST90470306 | 2.22e-03 |
| 8579 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 65) | GCST90320884 | 2.22e-03 |
| 8580 | Glutamine levels | GCST90092818 | 2.22e-03 |
| 8581 | CD69/SNAP23 ratio | GCST90313886 | 2.22e-03 |
| 8582 | CXCL5/SDC4 ratio | GCST90314353 | 2.21e-03 |
| 8583 | F2R/GP6 ratio | GCST90314730 | 2.20e-03 |
| 8584 | NFASC levels | GCST90470031 | 2.20e-03 |
| 8585 | Cholesteryl ester_14:0_[M+NH4]1+ levels | GCST90060197 | 2.20e-03 |
| 8586 | Total fatty acid levels | GCST90502711 | 2.19e-03 |
| 8587 | Retinal venular tortuosity | GCST90270399 | 2.19e-03 |
| 8588 | Eosinophil count | GCST90025987 | 2.19e-03 |
| 8589 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T490 | ECGU000490 | 2.19e-03 |
| 8590 | Estimated glomerular filtration rate (cystatin c) | GCST90428448 | 2.18e-03 |
| 8591 | Cholesterol to total lipids in very large HDL percentage (UKB data field 23630) | GCST90269727 | 2.18e-03 |
| 8592 | Left-hemisphere dorsal attention network to left-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302690 | 2.18e-03 |
| 8593 | Free cholesterol levels in small HDL | GCST90092948 | 2.17e-03 |
| 8594 | ATOX1/TMSB10 ratio | GCST90313377 | 2.17e-03 |
| 8595 | PEAR1/SNAP23 ratio | GCST90315643 | 2.17e-03 |
| 8596 | Blood cell traits latent factor 16 (white cell) | GCST90559258 | 2.17e-03 |
| 8597 | Left-hemisphere visual network to accumbens white-matter structural connectivity | GCST90302668 | 2.17e-03 |
| 8598 | PEAR1/PECAM1 ratio | GCST90315641 | 2.16e-03 |
| 8599 | BST2 levels | GCST90468475 | 2.16e-03 |
| 8600 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T220 | ECGU000220 | 2.16e-03 |
| 8601 | IDP dMRI ProbtrackX L1 cgh l | GCST90004252 | 2.15e-03 |
| 8602 | DTI autoptx L1 ptr l tract | GCST90385158 | 2.15e-03 |
| 8603 | Diacylglycerol_36:5_[M+H-H2O]1+ levels | GCST90060187 | 2.15e-03 |
| 8604 | PLTP levels | GCST90470262 | 2.15e-03 |
| 8605 | DTI TBSS MO Pontine crossing tract | GCST90384621 | 2.15e-03 |
| 8606 | TAB2 levels | GCST90470796 | 2.14e-03 |
| 8607 | IFIT3 levels | GCST90241571 | 2.14e-03 |
| 8608 | RAB11FIP3 levels | GCST90470404 | 2.14e-03 |
| 8609 | CD160/KLRB1 ratio | GCST90313731 | 2.13e-03 |
| 8610 | CD84/GP6 ratio | GCST90313914 | 2.13e-03 |
| 8611 | CDKN2D/TACC3 ratio | GCST90313992 | 2.12e-03 |
| 8612 | CCL11 levels | GCST90274764 | 2.12e-03 |
| 8613 | MB levels | GCST90469869 | 2.11e-03 |
| 8614 | Total lipids in medium VLDL | GCST90498994 | 2.10e-03 |
| 8615 | Percentage of FA2G1 in total neutral plasma glycans (GPn) (GP61) | GCST90668505 | 2.10e-03 |
| 8616 | EGLN1 levels | GCST90469087 | 2.09e-03 |
| 8617 | Total protein levels | GCST90018756 | 2.09e-03 |
| 8618 | Phosphatidate_34:2_[M-H]1- levels | GCST90060223 | 2.09e-03 |
| 8619 | NT5C levels | GCST90470092 | 2.09e-03 |
| 8620 | FSTL3 levels | GCST90469272 | 2.09e-03 |
| 8621 | Total lipids in HDL (UKB data field 23426) | GCST90269523 | 2.08e-03 |
| 8622 | C1RL levels | GCST90468492 | 2.08e-03 |
| 8623 | Type 1 diabetes | GCST90000529 | 2.08e-03 |
| 8624 | TIRAP levels | GCST90243032 | 2.07e-03 |
| 8625 | Monounsaturated fatty acid levels | GCST90502346 | 2.07e-03 |
| 8626 | Free cholesterol in medium HDL (UKB data field 23570) | GCST90269667 | 2.07e-03 |
| 8627 | VPS4B levels | GCST90471047 | 2.06e-03 |
| 8628 | FOXO1/IRAK4 ratio | GCST90314870 | 2.06e-03 |
| 8629 | MIF/SUSD2 ratio | GCST90315452 | 2.06e-03 |
| 8630 | Immature reticulocyte fraction (UKB data field 30280) | GCST90468079 | 2.06e-03 |
| 8631 | eosinophil (fraction, mean, inv-norm transformed) | GCST90475300 | 2.05e-03 |
| 8632 | HDL x anxiety interaction (2df test) | GCST90570665 | 2.05e-03 |
| 8633 | PDGFA/USP8 ratio | GCST90315621 | 2.05e-03 |
| 8634 | BAG6/BMP6 ratio | GCST90313450 | 2.05e-03 |
| 8635 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 103) | GCST90320922 | 2.05e-03 |
| 8636 | Saturated fatty acids levels | GCST90502192 | 2.05e-03 |
| 8637 | GIPC2 levels | GCST90469347 | 2.05e-03 |
| 8638 | IDP dMRI TBSS ICVF Fornix cres+Stria terminalis L | GCST90004366 | 2.05e-03 |
| 8639 | Mean corpuscular volume (UKB data field 30040) | GCST90468086 | 2.05e-03 |
| 8640 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 81) | GCST90320644 | 2.05e-03 |
| 8641 | CNP levels | GCST90468798 | 2.04e-03 |
| 8642 | Total concentration of lipoprotein particles | GCST90500101 | 2.04e-03 |
| 8643 | ROBO1/SPON1 ratio | GCST90315783 | 2.04e-03 |
| 8644 | Stable angina pectoris | GCST90018695 | 2.03e-03 |
| 8645 | Triacylglycerol (50:0) [NL-18:0] levels | GCST90025151 | 2.03e-03 |
| 8646 | Plasma homoarginine levels in chronic kidney disease | GCST90265345 | 2.02e-03 |
| 8647 | BAMBI levels | GCST90468420 | 2.02e-03 |
| 8648 | EFEMP1/FSTL3 ratio | GCST90314595 | 2.02e-03 |
| 8649 | B4GALT1/IFNGR1 ratio | GCST90313430 | 2.02e-03 |
| 8650 | Acquired toe deformities (PheCode 735.2) | GCST90476249 | 2.02e-03 |
| 8651 | EIF4G1/TBC1D23 ratio | GCST90314639 | 2.01e-03 |
| 8652 | GZMA levels | GCST90241323 | 2.01e-03 |
| 8653 | GTPBP2 levels | GCST90469417 | 2.01e-03 |
| 8654 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498101 | 2.01e-03 |
| 8655 | CD200/CLEC4G ratio | GCST90313746 | 2.01e-03 |
| 8656 | Triglyceride to phosphoglyceride ratio | GCST90454483 | 2.01e-03 |
| 8657 | CA9 levels | GCST90468518 | 2.01e-03 |
| 8658 | DTI TBSS L3 Superior cerebellar peduncle R | GCST90384536 | 2.01e-03 |
| 8659 | Triacylglycerol_50:4_[M+NH4]1+ levels | GCST90060466 | 2.00e-03 |
| 8660 | PRTN3/RETN ratio | GCST90315734 | 2.00e-03 |
| 8661 | mean corpuscular volume (MCV, mean, inv-norm transformed) | GCST90475470 | 2.00e-03 |
| 8662 | EIF4E levels | GCST90469096 | 2.00e-03 |
| 8663 | T1 FreeSurfer DKT lh precentral thickness | GCST90384246 | 2.00e-03 |
| 8664 | Ascending aorta distensibility | GCST90267385 | 1.99e-03 |
| 8665 | Clonal haematopoiesis of indeterminate potential (TET2 mutation) | GCST90165281 | 1.99e-03 |
| 8666 | Eosinophil percentage of white cells | GCST90002382 | 1.99e-03 |
| 8667 | Triglycerides to Total Lipids in IDL percentage | GCST90497682 | 1.98e-03 |
| 8668 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502648 | 1.98e-03 |
| 8669 | CELA3A/CTRC ratio | GCST90314012 | 1.98e-03 |
| 8670 | OPHN1 levels | GCST90470126 | 1.98e-03 |
| 8671 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 119) | GCST90320682 | 1.98e-03 |
| 8672 | FOXO1/MAP4K5 ratio | GCST90314872 | 1.98e-03 |
| 8673 | Fractured bone site(s) - Other bones | Medical conditions | UKBB00000256 | 1.98e-03 |
| 8674 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 24) | GCST90320587 | 1.98e-03 |
| 8675 | Eosinophill percentage | Blood count | UKBB00000207 | 1.97e-03 |
| 8676 | WFDC5 levels | GCST90089598 | 1.97e-03 |
| 8677 | Triacylglycerol_52:4_[M+NH4]1+ levels | GCST90060508 | 1.97e-03 |
| 8678 | aparc-DKTatlas lh area precentral | GCST90003256 | 1.97e-03 |
| 8679 | Pulse pressure, automated reading, adjusted by medication | Cardiovascular measurement | UKBB00000717 | 1.97e-03 |
| 8680 | aseg lh volume Cerebellum-Cortex | GCST90002619 | 1.96e-03 |
| 8681 | Atopic/contact dermatitis due to other or unspecified (PheCode 939) | GCST90476289 | 1.96e-03 |
| 8682 | Thyroid peroxidase antibody levels in pregnancy | GCST90435201 | 1.96e-03 |
| 8683 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T134 | ECGU000134 | 1.96e-03 |
| 8684 | KDR/VWF ratio | GCST90315245 | 1.96e-03 |
| 8685 | Eustachian tube disorders (PheCode 381.2) | GCST90475904 | 1.96e-03 |
| 8686 | Carotid plaque | GCST007435 | 1.96e-03 |
| 8687 | REG3A levels | GCST90470449 | 1.96e-03 |
| 8688 | TFF3 levels | GCST90470837 | 1.95e-03 |
| 8689 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T482 | ECGU000482 | 1.95e-03 |
| 8690 | CPA1/CPB1 ratio | GCST90314202 | 1.95e-03 |
| 8691 | CLIP2/LAT2 ratio | GCST90314128 | 1.95e-03 |
| 8692 | aparc-a2009s lh area G-cingul-Post-ventral | GCST90003306 | 1.95e-03 |
| 8693 | CXCL11/VTA1 ratio | GCST90314337 | 1.95e-03 |
| 8694 | Citrulline levels | GCST90200403 | 1.94e-03 |
| 8695 | LONP1 levels | GCST90469785 | 1.94e-03 |
| 8696 | Vanillylmandelate (VMA) levels | GCST90200309 | 1.94e-03 |
| 8697 | METAP2/RILP ratio | GCST90315433 | 1.94e-03 |
| 8698 | IDS levels | GCST90469507 | 1.94e-03 |
| 8699 | ERBB4 levels | GCST90469141 | 1.94e-03 |
| 8700 | DMP1 levels | GCST90469007 | 1.94e-03 |
| 8701 | IDP T1 FAST ROIs brain stem | GCST90002561 | 1.94e-03 |
| 8702 | SAMD9L levels | GCST90470524 | 1.93e-03 |
| 8703 | Total cholines levels | GCST90497183 | 1.93e-03 |
| 8704 | CAG-269 sp001915995 abundance in stool | GCST90032266 | 1.92e-03 |
| 8705 | CCL17/F2R ratio | GCST90313686 | 1.92e-03 |
| 8706 | Non-cancer illness code, self-reported - asthma | Medical conditions | UKBB00000506 | 1.92e-03 |
| 8707 | PRR15 levels | GCST90424790 | 1.92e-03 |
| 8708 | ERBIN/TBC1D23 ratio | GCST90314698 | 1.92e-03 |
| 8709 | Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093049 | 1.92e-03 |
| 8710 | Actinic keratosis | FING00000013 | 1.91e-03 |
| 8711 | Comorbidity of gastric and duodenal ulcers | GCST90270929 | 1.91e-03 |
| 8712 | Other non-epithelial cancer of skin | neoplasms | UKBB00000615 | 1.91e-03 |
| 8713 | Chronic obstructive pulmonary disease in current smokers | GCST90016593 | 1.91e-03 |
| 8714 | DUSP3 levels | GCST90469053 | 1.90e-03 |
| 8715 | CD27/TNFRSF13B ratio | GCST90313777 | 1.90e-03 |
| 8716 | DSG3/DSG4 ratio | GCST90314558 | 1.90e-03 |
| 8717 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T188 | ECGA000188 | 1.90e-03 |
| 8718 | aparc-DKTatlas rh area cuneus | GCST90003268 | 1.90e-03 |
| 8719 | EDAR/TNFSF12 ratio | GCST90314591 | 1.89e-03 |
| 8720 | AGRP levels | GCST90012063 | 1.89e-03 |
| 8721 | CD160/NCR1 ratio | GCST90313732 | 1.88e-03 |
| 8722 | Right-hemisphere visual network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302777 | 1.88e-03 |
| 8723 | 1-margaroyl-2-linoleoyl-GPC (17:0/18:2) metabolite level | GCST90616013 | 1.88e-03 |
| 8724 | Lysophosphatidylcholine (26:0) [sn1] levels | GCST90024188 | 1.87e-03 |
| 8725 | PPP1R12A/SKAP2 ratio | GCST90315710 | 1.87e-03 |
| 8726 | ADAM22 levels | GCST90468218 | 1.87e-03 |
| 8727 | Atrial fibrillation/atrial flutter | GCST90018576 | 1.87e-03 |
| 8728 | DTI TBSS MD Sagittal stratum R | GCST90384602 | 1.87e-03 |
| 8729 | IL5RA/TNFRSF13B ratio | GCST90315164 | 1.87e-03 |
| 8730 | BTD levels | GCST90468477 | 1.87e-03 |
| 8731 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 82) | GCST90320645 | 1.86e-03 |
| 8732 | DNAJB6 levels | GCST90469014 | 1.86e-03 |
| 8733 | FAM3B/GPA33 ratio | GCST90314778 | 1.86e-03 |
| 8734 | HTRA2/SNAP29 ratio | GCST90315098 | 1.86e-03 |
| 8735 | Arm predicted mass (right) | Impedance measures | UKBB00000050 | 1.85e-03 |
| 8736 | OBP2B levels | GCST90470113 | 1.85e-03 |
| 8737 | HAMP levels | GCST90451683 | 1.85e-03 |
| 8738 | Asthma | GCST90014325 | 1.85e-03 |
| 8739 | Other malignant neoplasms of skin | Melanoma and other malignant neoplasms of skin | UKBB00000613 | 1.85e-03 |
| 8740 | JAM2/TNFRSF19 ratio | GCST90315241 | 1.85e-03 |
| 8741 | F7 levels | GCST90469171 | 1.84e-03 |
| 8742 | Free cholesterol to total lipids in large VLDL percentage (UKB data field 23592) | GCST90269689 | 1.84e-03 |
| 8743 | TMSB10/TREML2 ratio | GCST90315923 | 1.84e-03 |
| 8744 | Hippocampal subfield left CA3 volume (head) | GCST90267941 | 1.84e-03 |
| 8745 | NOTCH1/TIE1 ratio | GCST90315546 | 1.84e-03 |
| 8746 | 4-hydroxyglutamate levels | GCST90199890 | 1.84e-03 |
| 8747 | Lymphoid neoplasms (P-cell phenocluster) | GCST90624737 | 1.84e-03 |
| 8748 | Hematocrit | GCST90002304 | 1.83e-03 |
| 8749 | GPNMB levels | GCST90469393 | 1.83e-03 |
| 8750 | EPHB4/ESAM ratio | GCST90314679 | 1.83e-03 |
| 8751 | RGMB/SMOC2 ratio | GCST90315770 | 1.83e-03 |
| 8752 | RETN levels | GCST90470457 | 1.82e-03 |
| 8753 | CDC37/SNX9 ratio | GCST90313936 | 1.82e-03 |
| 8754 | TNR levels | GCST90470929 | 1.82e-03 |
| 8755 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T108 | ECGU000108 | 1.81e-03 |
| 8756 | PMVK levels | GCST90470272 | 1.81e-03 |
| 8757 | Retinal thickness (functional principal component 1) | GCST90455721 | 1.81e-03 |
| 8758 | Pelvic organ prolapse | GCST90102470 | 1.81e-03 |
| 8759 | DTI autoptx MD unc r tract | GCST90385246 | 1.81e-03 |
| 8760 | Inguinal hernia (PheCode 550.1) | GCST90476060 | 1.81e-03 |
| 8761 | Docosahexaenoic acid levels | GCST90501986 | 1.81e-03 |
| 8762 | Calcium | Blood biochemistry | UKBB00000114 | 1.81e-03 |
| 8763 | Ovarian cancer-related tumor marker CA 125 levels | GCST90012078 | 1.80e-03 |
| 8764 | HDL cholesterol | GCST90018736 | 1.80e-03 |
| 8765 | REG1A/REG3A ratio | GCST90315761 | 1.79e-03 |
| 8766 | CXCL5/SPARC ratio | GCST90314355 | 1.79e-03 |
| 8767 | MYOC/RGMB ratio | GCST90315508 | 1.79e-03 |
| 8768 | VSIG2 levels | GCST90471051 | 1.78e-03 |
| 8769 | CCL11/CCL2 ratio | GCST90313672 | 1.78e-03 |
| 8770 | GZMH levels | GCST90469425 | 1.78e-03 |
| 8771 | ERP44/SUMF2 ratio | GCST90314710 | 1.78e-03 |
| 8772 | Bone marrow fat fraction of lumbar vertebra 1 | GCST90652386 | 1.78e-03 |
| 8773 | FABP6 levels | GCST90469178 | 1.77e-03 |
| 8774 | KLK11/KLK8 ratio | GCST90315254 | 1.76e-03 |
| 8775 | Right hippocampal volume | GCST90267974 | 1.76e-03 |
| 8776 | Mean corpuscular hemoglobin concentration | GCST90002329 | 1.76e-03 |
| 8777 | MED18/SH2B3 ratio | GCST90315412 | 1.75e-03 |
| 8778 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T259 | ECGU000259 | 1.75e-03 |
| 8779 | T1 FreeSurfer pial rh lateraloccipital area | GCST90385832 | 1.75e-03 |
| 8780 | DTI TBSS L3 Sagittal stratum L | GCST90384555 | 1.74e-03 |
| 8781 | Total fatty acid levels | GCST90502218 | 1.74e-03 |
| 8782 | GSTA1 levels | GCST90469411 | 1.74e-03 |
| 8783 | HCLS1/LAT ratio | GCST90315041 | 1.74e-03 |
| 8784 | CXCL3/CXCL5 ratio | GCST90314344 | 1.74e-03 |
| 8785 | CTSZ levels | GCST90468918 | 1.74e-03 |
| 8786 | hematocrit (mean, inv-norm transformed) | GCST90475341 | 1.73e-03 |
| 8787 | Left-hemisphere control network to accumbens white-matter structural connectivity | GCST90302758 | 1.73e-03 |
| 8788 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T149 | ECGU000149 | 1.73e-03 |
| 8789 | Hemoglobin concentration | GCST90002311 | 1.72e-03 |
| 8790 | SFTPA2/SFTPD ratio | GCST90315839 | 1.72e-03 |
| 8791 | aparc-a2009s rh area S-collat-transv-ant | GCST90003420 | 1.72e-03 |
| 8792 | Acute sinusitis | FING00000031 | 1.72e-03 |
| 8793 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 122) | GCST90320941 | 1.71e-03 |
| 8794 | BPIFB1 levels | GCST90468462 | 1.71e-03 |
| 8795 | GDNF levels | GCST90469323 | 1.71e-03 |
| 8796 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T258 | ECGU000258 | 1.71e-03 |
| 8797 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T83 | ECGU000083 | 1.71e-03 |
| 8798 | Saturated fatty acid levels | GCST90092980 | 1.70e-03 |
| 8799 | CTSF/SMPDL3A ratio | GCST90314316 | 1.70e-03 |
| 8800 | Plasma glycocholenate sulfate* levels in chronic kidney disease | GCST90265291 | 1.70e-03 |
| 8801 | IDP T1 FAST ROIs L cerebellum crus I | GCST90002569 | 1.70e-03 |
| 8802 | Asthma | GCST90468112 | 1.69e-03 |
| 8803 | CCN2/EDAR ratio | GCST90313711 | 1.69e-03 |
| 8804 | Monounsaturated fatty acid levels | GCST90502036 | 1.69e-03 |
| 8805 | LYN/TACC3 ratio | GCST90315350 | 1.69e-03 |
| 8806 | BIN2/EREG ratio | GCST90313503 | 1.69e-03 |
| 8807 | IDP T1 FAST ROIs V cerebellum X | GCST90002588 | 1.69e-03 |
| 8808 | DNAJC6 levels | GCST90469017 | 1.68e-03 |
| 8809 | RGMB/TNFRSF21 ratio | GCST90315772 | 1.68e-03 |
| 8810 | CREG1/SMPDL3A ratio | GCST90314252 | 1.68e-03 |
| 8811 | NFKBIE levels | GCST90470039 | 1.68e-03 |
| 8812 | Lymphangioleiomyomatosis (sporadic) | GCST008311 | 1.68e-03 |
| 8813 | CCL17/CCL22 ratio | GCST90313682 | 1.68e-03 |
| 8814 | Seborrhoeic dermatitis | FING00001282 | 1.68e-03 |
| 8815 | REG1B levels | GCST90470448 | 1.68e-03 |
| 8816 | PON3 levels | GCST90470287 | 1.67e-03 |
| 8817 | CCL13/CCL2 ratio | GCST90313675 | 1.67e-03 |
| 8818 | Omega-6 fatty acid levels | GCST90502095 | 1.67e-03 |
| 8819 | Waist circumference adjusted for body mass index | GCST90020029 | 1.67e-03 |
| 8820 | Other disorders of fluid, electrolyte and acid-base balance | FING00001027 | 1.67e-03 |
| 8821 | DPEP2 levels | GCST90469031 | 1.67e-03 |
| 8822 | Omega-3 fatty acid levels | GCST90502055 | 1.67e-03 |
| 8823 | aparc-a2009s lh volume G-oc-temp-med-Lingual | GCST90002946 | 1.66e-03 |
| 8824 | RGMB/THY1 ratio | GCST90315771 | 1.66e-03 |
| 8825 | aparc-a2009s lh area S-collat-transv-ant | GCST90003346 | 1.66e-03 |
| 8826 | Left-hemisphere limbic network to thalamus white-matter structural connectivity | GCST90302736 | 1.65e-03 |
| 8827 | BCL2L11/RAB6A ratio | GCST90313484 | 1.65e-03 |
| 8828 | FAM174A levels | GCST90241914 | 1.65e-03 |
| 8829 | DLL1/NECTIN4 ratio | GCST90314497 | 1.65e-03 |
| 8830 | Cholesterol, total | GCST000760 | 1.65e-03 |
| 8831 | SMPD1 levels | GCST90470684 | 1.65e-03 |
| 8832 | CD274/EFNA4 ratio | GCST90313768 | 1.65e-03 |
| 8833 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T115 | ECGA000115 | 1.64e-03 |
| 8834 | Liver enzyme levels (alanine transaminase) | GCST90013405 | 1.64e-03 |
| 8835 | CD164/SIAE ratio | GCST90313744 | 1.64e-03 |
| 8836 | Mean arterial pressure (BMI adjusted) | GCST90335169 | 1.64e-03 |
| 8837 | CANT1/ROR1 ratio | GCST90313620 | 1.64e-03 |
| 8838 | SEZ6L levels | GCST90470607 | 1.64e-03 |
| 8839 | CD83/LAMP3 ratio | GCST90313906 | 1.64e-03 |
| 8840 | Colorectal cancer (PheCode 153) | GCST008372 | 1.64e-03 |
| 8841 | NTN4 levels | GCST90242049 | 1.64e-03 |
| 8842 | SIGLEC10 levels | GCST90470630 | 1.64e-03 |
| 8843 | Sphingomyelin_40:2_[M+H]1+ levels | GCST90060352 | 1.63e-03 |
| 8844 | IDP T1 FAST ROIs R cerebellum X | GCST90002589 | 1.63e-03 |
| 8845 | T1 FreeSurfer DKT rh lateraloccipital volume | GCST90384357 | 1.63e-03 |
| 8846 | CTF1/ITGB1BP2 ratio | GCST90314305 | 1.63e-03 |
| 8847 | CD22 levels | GCST90468610 | 1.63e-03 |
| 8848 | GP1BA/SELP ratio | GCST90314958 | 1.63e-03 |
| 8849 | Thoracic aortic aneurysm | FING00001357 | 1.62e-03 |
| 8850 | Hearing difficulty and hearing difficulty with background noise | GCST90245776 | 1.62e-03 |
| 8851 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T121 | ECGU000121 | 1.62e-03 |
| 8852 | HippSubfield rh volume GC-ML-DG-head | GCST90002701 | 1.62e-03 |
| 8853 | PPP1R2/TMSB10 ratio | GCST90315721 | 1.62e-03 |
| 8854 | Androstenediol (3alpha, 17alpha) monosulfate (3) levels | GCST90199856 | 1.62e-03 |
| 8855 | IPCEF1/TBCB ratio | GCST90315187 | 1.62e-03 |
| 8856 | Thyroid peroxidase antibody positivity in pregnancy | GCST90435202 | 1.61e-03 |
| 8857 | TCL1A/TNFRSF13C ratio | GCST90315912 | 1.61e-03 |
| 8858 | EDN1 levels | GCST90469073 | 1.61e-03 |
| 8859 | Alkylphosphatidylcholine (O-16:0/16:0) levels | GCST90024913 | 1.61e-03 |
| 8860 | GSTT2 levels | GCST90086652 | 1.61e-03 |
| 8861 | PCDH17/THBD ratio | GCST90315607 | 1.60e-03 |
| 8862 | Asthma and allergy | FING00000115 | 1.60e-03 |
| 8863 | IDP T1 FAST ROIs L cerebellum V | GCST90002564 | 1.60e-03 |
| 8864 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497790 | 1.60e-03 |
| 8865 | Thyroid peroxidase antibody positivity with euthyroid in pregnancy | GCST90435203 | 1.60e-03 |
| 8866 | ANXA1 levels | GCST90468316 | 1.60e-03 |
| 8867 | ICAM2/SELE ratio | GCST90315120 | 1.60e-03 |
| 8868 | CD74/TNFRSF21 ratio | GCST90313897 | 1.60e-03 |
| 8869 | ERBB3/IL1R2 ratio | GCST90314689 | 1.60e-03 |
| 8870 | aseg lh intensity Accumbens-area | GCST90003774 | 1.60e-03 |
| 8871 | FCER2 levels | GCST90469199 | 1.59e-03 |
| 8872 | Prurigo nodularis | FING00001220 | 1.59e-03 |
| 8873 | rfMRI connectivity (ICA100 edge 931) | GCST90005784 | 1.59e-03 |
| 8874 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T119 | ECGA000119 | 1.59e-03 |
| 8875 | ENTPD6 levels | GCST90469122 | 1.59e-03 |
| 8876 | Triglycerides to Total Lipids in Medium LDL percentage | GCST90498881 | 1.58e-03 |
| 8877 | Linoleic acid to total fatty acids percentage | GCST90502337 | 1.58e-03 |
| 8878 | CA4/SELE ratio | GCST90313587 | 1.58e-03 |
| 8879 | DTYMK levels | GCST90469049 | 1.58e-03 |
| 8880 | Sphingomyelin_36:2_[M+H]1+ levels | GCST90060263 | 1.58e-03 |
| 8881 | DCTPP1 levels | GCST90468961 | 1.58e-03 |
| 8882 | PTPN1 levels | GCST90470376 | 1.57e-03 |
| 8883 | CASP3/MESD ratio | GCST90313636 | 1.57e-03 |
| 8884 | ATP5IF1/DECR1 ratio | GCST90313382 | 1.57e-03 |
| 8885 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T65 | ECGA000065 | 1.57e-03 |
| 8886 | CD22/TCL1A ratio | GCST90313760 | 1.57e-03 |
| 8887 | SHMT1 levels | GCST90470627 | 1.57e-03 |
| 8888 | MMP8/OLR1 ratio | GCST90315464 | 1.56e-03 |
| 8889 | DHEAS levels | GCST90199673 | 1.56e-03 |
| 8890 | ANGPT1/CPXM1 ratio | GCST90313262 | 1.56e-03 |
| 8891 | SERPINF2 levels | GCST90470599 | 1.56e-03 |
| 8892 | BCAM levels | GCST90468425 | 1.56e-03 |
| 8893 | Calcium levels | GCST90018731 | 1.56e-03 |
| 8894 | IDP dMRI TBSS ISOVF Posterior thalamic radiation L | GCST90004506 | 1.56e-03 |
| 8895 | NPL levels | GCST90470072 | 1.56e-03 |
| 8896 | Free cholesterol in HDL (UKB data field 23422) | GCST90269519 | 1.56e-03 |
| 8897 | OLR1/PLAUR ratio | GCST90315584 | 1.56e-03 |
| 8898 | Concentration of medium HDL particles (UKB data field 23565) | GCST90269662 | 1.56e-03 |
| 8899 | CALCOCO1/PDLIM7 ratio | GCST90313607 | 1.55e-03 |
| 8900 | Triglyceride levels in very large HDL | GCST90093014 | 1.55e-03 |
| 8901 | Volume of left accessory basal nucleus | GCST90474874 | 1.54e-03 |
| 8902 | PNMA1 levels | GCST90470276 | 1.54e-03 |
| 8903 | Phosphatidylcholine levels | GCST90499240 | 1.54e-03 |
| 8904 | ACVRL1/TNFRSF9 ratio | GCST90313160 | 1.54e-03 |
| 8905 | MAVS/ZBTB16 ratio | GCST90315401 | 1.54e-03 |
| 8906 | FABP1/RBP2 ratio | GCST90314753 | 1.53e-03 |
| 8907 | IST1 levels | GCST90469632 | 1.53e-03 |
| 8908 | Free testosterone levels | GCST90239826 | 1.53e-03 |
| 8909 | Skin color (cheek, ITA value) | GCST90502780 | 1.53e-03 |
| 8910 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 114) | GCST90320677 | 1.53e-03 |
| 8911 | DTNB levels | GCST90469046 | 1.53e-03 |
| 8912 | RBPMS2 levels | GCST90470441 | 1.52e-03 |
| 8913 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498550 | 1.52e-03 |
| 8914 | PPP1R12A/TXNDC5 ratio | GCST90315714 | 1.52e-03 |
| 8915 | FABP2/LGALS4 ratio | GCST90314756 | 1.52e-03 |
| 8916 | ARSA/CD164 ratio | GCST90313351 | 1.52e-03 |
| 8917 | DLL1/NOTCH1 ratio | GCST90314498 | 1.52e-03 |
| 8918 | Fat-free mass | GCST007063 | 1.51e-03 |
| 8919 | Varicose veins of lower extremity, symptomtic (PheCode 454.11) | GCST90476014 | 1.51e-03 |
| 8920 | Primary angle-closure glaucoma | FING00001210 | 1.51e-03 |
| 8921 | Omega-6 fatty acid levels | GCST90502514 | 1.50e-03 |
| 8922 | LRIG3 levels | GCST90469795 | 1.50e-03 |
| 8923 | CALCOCO2 levels | GCST90468531 | 1.50e-03 |
| 8924 | IPCEF1 levels | GCST90469624 | 1.50e-03 |
| 8925 | IDP dMRI TBSS FA External capsule L | GCST90003910 | 1.49e-03 |
| 8926 | FGFBP3 levels | GCST90469232 | 1.49e-03 |
| 8927 | Hyperparathyroidism (PheCode 252.1) | GCST90475693 | 1.49e-03 |
| 8928 | Rheumatoid arthritis | GCST90132223 | 1.49e-03 |
| 8929 | CMIP levels | GCST90468795 | 1.49e-03 |
| 8930 | ADH4 levels | GCST90468244 | 1.49e-03 |
| 8931 | eGFR in diabetes mellitus (strict) case-control group (minimal adjustment) | GCST90624781 | 1.49e-03 |
| 8932 | MAVS levels | GCST90469866 | 1.49e-03 |
| 8933 | aparc-a2009s lh area S-calcarine | GCST90003340 | 1.48e-03 |
| 8934 | Sphingomyelin_40:0_[M+H]1+ levels | GCST90060364 | 1.48e-03 |
| 8935 | Volume of right anterior amygdaloid area | GCST90474904 | 1.48e-03 |
| 8936 | COL18A1 levels | GCST90468812 | 1.48e-03 |
| 8937 | LAYN levels | GCST90469742 | 1.48e-03 |
| 8938 | Eosinophil count | GCST90002298 | 1.48e-03 |
| 8939 | BA-exvivo lh volume entorhinal | GCST90002848 | 1.48e-03 |
| 8940 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T483 | ECGU000483 | 1.48e-03 |
| 8941 | Cholesteryl Esters in IDL | GCST90497525 | 1.47e-03 |
| 8942 | CPXM1/DKK1 ratio | GCST90314218 | 1.47e-03 |
| 8943 | SCARF2 levels | GCST90470537 | 1.47e-03 |
| 8944 | Corneal hysteresis (left) | Intraocular pressure | UKBB00000148 | 1.46e-03 |
| 8945 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T104 | ECGU000104 | 1.46e-03 |
| 8946 | MAVS/MED18 ratio | GCST90315389 | 1.46e-03 |
| 8947 | LDLR/PCSK9 ratio | GCST90315311 | 1.46e-03 |
| 8948 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T189 | ECGA000189 | 1.45e-03 |
| 8949 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 93) | GCST90320912 | 1.45e-03 |
| 8950 | Eosinophil count | GCST90002381 | 1.45e-03 |
| 8951 | METAP2/PLPBP ratio | GCST90315432 | 1.45e-03 |
| 8952 | red cell diameter width (RDW, maximum, inv-norm transformed) | GCST90476357 | 1.45e-03 |
| 8953 | AIDA levels | GCST90468265 | 1.45e-03 |
| 8954 | CD164/LGMN ratio | GCST90313741 | 1.45e-03 |
| 8955 | LAIR2 levels | GCST90469729 | 1.45e-03 |
| 8956 | CSRP3 levels | GCST90468892 | 1.44e-03 |
| 8957 | IDP dMRI ProbtrackX MO str l | GCST90004023 | 1.44e-03 |
| 8958 | Oral glucose tolerance test-2h | GCST90566423 | 1.44e-03 |
| 8959 | Rheumatoid arthritis and other inflammatory (PheCode 714) | GCST90476228 | 1.44e-03 |
| 8960 | FCRL1 levels | GCST90469205 | 1.44e-03 |
| 8961 | hematocrit (maximum, inv-norm transformed) | GCST90475338 | 1.44e-03 |
| 8962 | LDLRAP1 levels | GCST90469749 | 1.44e-03 |
| 8963 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T225 | ECGU000225 | 1.43e-03 |
| 8964 | CD59/PI3 ratio | GCST90313858 | 1.43e-03 |
| 8965 | Ribothymidine levels in chronic kidney disease | GCST90257554 | 1.42e-03 |
| 8966 | Right-hemisphere default mode network to hippocampus white-matter structural connectivity | GCST90302848 | 1.42e-03 |
| 8967 | DCTD levels | GCST90468957 | 1.42e-03 |
| 8968 | CLEC1B/HBEGF ratio | GCST90314092 | 1.42e-03 |
| 8969 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T90 | ECGA000090 | 1.42e-03 |
| 8970 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T486 | ECGU000486 | 1.42e-03 |
| 8971 | Monounsaturated fatty acids levels (UKB data field 23447) | GCST90269544 | 1.42e-03 |
| 8972 | Total lipids in very small VLDL (UKB data field 23517) | GCST90269614 | 1.42e-03 |
| 8973 | IDP dMRI ProbtrackX MO atr r | GCST90004003 | 1.42e-03 |
| 8974 | ALDH1A1/PKLR ratio | GCST90313245 | 1.41e-03 |
| 8975 | HDL cholesterol levels | GCST90497340 | 1.41e-03 |
| 8976 | Right hippocampal volume (tail) | GCST90267973 | 1.41e-03 |
| 8977 | KAZALD1 levels | GCST90469665 | 1.41e-03 |
| 8978 | Bell's palsy | FING00000144 | 1.41e-03 |
| 8979 | Aortic aneurysm | FING00000102 | 1.41e-03 |
| 8980 | CKAP4/TNFRSF4 ratio | GCST90314076 | 1.41e-03 |
| 8981 | AARSD1/UBAC1 ratio | GCST90313135 | 1.41e-03 |
| 8982 | SCARF1 levels | GCST90470536 | 1.41e-03 |
| 8983 | Immature fraction of reticulocytes | GCST90025971 | 1.40e-03 |
| 8984 | Mean spheric corpuscular volume | GCST90002397 | 1.40e-03 |
| 8985 | DOK1 levels | GCST90469028 | 1.40e-03 |
| 8986 | DTI TBSS L3 Posterior thalamic radiation R | GCST90384552 | 1.40e-03 |
| 8987 | FIS1/HSPA1A ratio | GCST90314825 | 1.39e-03 |
| 8988 | ROR1 levels | GCST90470492 | 1.39e-03 |
| 8989 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T96 | ECGU000096 | 1.39e-03 |
| 8990 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T112 | ECGA000112 | 1.39e-03 |
| 8991 | CD300A levels | GCST90468619 | 1.39e-03 |
| 8992 | Eosinophil count | GCST90002299 | 1.39e-03 |
| 8993 | PDAP1 levels | GCST90470179 | 1.38e-03 |
| 8994 | CLEC11A levels | GCST90468764 | 1.38e-03 |
| 8995 | Triacylglycerol_52:5_[M+NH4]1+ levels | GCST90060506 | 1.38e-03 |
| 8996 | CD79B/TNFRSF4 ratio | GCST90313903 | 1.38e-03 |
| 8997 | FOXO1/SNAP23 ratio | GCST90314875 | 1.38e-03 |
| 8998 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 102) | GCST90320921 | 1.38e-03 |
| 8999 | ADGRE2/IFNGR1 ratio | GCST90313177 | 1.38e-03 |
| 9000 | Urine adenosine levels in chronic kidney disease | GCST90264757 | 1.38e-03 |